<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03108027</url>
  </required_header>
  <id_info>
    <org_study_id>CQVM149B2209</org_study_id>
    <secondary_id>2017-000644-17</secondary_id>
    <nct_id>NCT03108027</nct_id>
  </id_info>
  <brief_title>Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma</brief_title>
  <acronym>QVM149</acronym>
  <official_title>A Randomized, Double-blind, Repeat Dose Cross-over Study to Assess the Bronchodilator Effects of Once Daily QVM149 Following Morning or Evening Dosing for 14 Days Compared to Placebo in Patients With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a randomized, placebo-controlled, double-blind, six-sequence, three-period
      cross-over study in asthma patients. The study consisted of a 14-day screening period,
      followed by a 14-day run-in period, and a treatment epoch which consists of three treatment
      periods, with a minimum duration of 14 days each followed (for the 2 first treatment periods)
      by a wash-out period. The duration of each treatment period may be extended up to a duration
      of 18 days if needed for operational reasons. The third treatment period was followed by a
      Study Completion evaluation at 1-7 days following the last dose. The treatment periods were
      separated by wash-out periods of 14 to 21 days duration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 26, 2017</start_date>
  <completion_date type="Actual">February 24, 2018</completion_date>
  <primary_completion_date type="Actual">February 24, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This study is to assess the bronchodilator effects of QVM149 dosed once daily either in the morning or in the evening for 2 weeks compared to placebo. It will provide evidence of the comparability of lung function effects of QVM149 irrespective of the administration schedule</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This is a double-blind masking.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 Standardized Area Under the Curve (AUC 0-24h) After Last Evening Dose of 14-day Treatment Period</measure>
    <time_frame>At the end of each treatment period day 14 pre-dose to 24 hours post-dose.</time_frame>
    <description>Weighted mean forced expiratory volume in 1 second (FEV1) over 24 h (AUC0-24h) following 14 days of treatment with QVM149 dosed in the morning, QVM149 dosed in the evening and placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough FEV1 After 24h</measure>
    <time_frame>At the end of each treatment period day 14 pre-dose to 24 hours post-dose.</time_frame>
    <description>FEV1 at approximately 24 h after the last p.m. or penultimate a.m. dose. Morning and evening trough FEV1 (L) were analyzed by time of day. For morning trough FEV1 (L) assessments this meant that the spirometric assessment was done approximately 24 h after last morning dose and approximately 12 h after last evening dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Expiratory Flow (PEF)</measure>
    <time_frame>From treatment period start through study completion (up to 19 weeks).</time_frame>
    <description>Peak expiratory flow (PEF) is the maximum flow generated during a forceful exhalation, starting from full lung inflationDaily morning and evening peak expiratory flow rate from Day 2 to Day14 during the three treatment periods.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive in a sequential order the following interventional treatments: A,B and C.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive in a sequential order the following interventional treatments: B, A and C.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive in a sequential order the following interventional treatments: C, B and A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive in a sequential order the following interventional treatments : C, A and B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive in a sequential order the following interventional treatments: A, C and B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive in a sequential order the following interventional treatments: B, C and A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)</intervention_name>
    <description>Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)</intervention_name>
    <description>QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment C: Placebo (morning dose) and placebo (evening dose)</intervention_name>
    <description>Placebo (morning dose) and placebo (evening dose)</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_label>Sequence 5</arm_group_label>
    <arm_group_label>Sequence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with a documented physician diagnosis of asthma and who additionally meet the
        following criteria:

          -  Patients receiving daily treatment with an inhaled corticosteroid at a low or medium
             daily dose

          -  On a stable regimen for at least 4 weeks prior to screening.

               -  Pre-bronchodilator FEV1 ≥ 60 % and &lt; 100% of the predicted normal value for the
                  patient during screening.

               -  Patients who demonstrate an increase in FEV1 of ≥ 12 % and ≥ 200 mL after
                  administration of 400 μg salbutamol/360 μg albuterol (or equivalent dose) at
                  Screening. All patients must perform a reversibility test at Screening.

               -  At screening, and baseline (day 1 pre-dose time) of the first treatment period,
                  vital signs (systolic and diastolic blood pressure and pulse rate) will be
                  assessed in the sitting position and again in the standing position as outlined
                  in the SOM. Sitting and standing vital signs should be within the following
                  ranges:

          -  oral body temperature between 35.0-37.5 °C

          -  systolic blood pressure, 90-159 mmHg

          -  diastolic blood pressure, 50-99 mmHg

          -  pulse rate, 40-90 bpm

               -  Hypertensive patients must have been on stable antihypertensive therapy for at
                  least 4 weeks prior to screening to be included in the trial.

               -  Patients must weigh at least 50 kg at screening to participate in the study, and
                  must have a body mass index (BMI) within the range of 18 to 40 kg/m2.

        Exclusion Criteria:

          -  Contraindicated for treatment with, or having a history of reactions/ hypersensitivity
             to any of the drugs of a similar class

          -  Patients who have had an asthma attack/exacerbation requiring systemic steroids or
             hospitalization or emergency room visit within 1 year of Screening.

          -  Patients who have had previous intubation for a severe asthma ttack/exacerbation.

          -  Patients with a history of clinically relevant bronchoconstriction upon repeated
             forced expiratory maneuvers.

          -  History of paradoxical bronchospasm in response to inhaled medicines.

          -  Patients who during the run-in period prior to randomization require the use of ≥12
             puffs / 24 hours of rescue medication for 48 hours (over two consecutive days) or who
             have a decline in PEF from the reference PEFof ≥ 30% for 6 consecutive scheduled PEF
             readings

          -  Patients who do not maintain regular day/night, waking/sleeping cycles (e.g., night
             shift workers).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt Am Main Hessen</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>22947</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Groningen</city>
        <state>GZ</state>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Machester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 23, 2017</study_first_submitted>
  <study_first_submitted_qc>April 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <results_first_submitted>February 22, 2019</results_first_submitted>
  <results_first_submitted_qc>May 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 21, 2019</results_first_posted>
  <last_update_submitted>May 20, 2019</last_update_submitted>
  <last_update_submitted_qc>May 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>QVM149,</keyword>
  <keyword>asthma,</keyword>
  <keyword>allergic asthma,</keyword>
  <keyword>allergy triggered asthma,</keyword>
  <keyword>reactive asthma,</keyword>
  <keyword>asthma attack,</keyword>
  <keyword>difficulty breathing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT03108027/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 8, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT03108027/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1</title>
          <description>Patients received in a sequential order the following interventional treatments: A,B and C.</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2</title>
          <description>Patients received in a sequential order the following interventional treatments: B, A and C.</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3</title>
          <description>Patients received in a sequential order the following interventional treatments: C, B and A.</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4</title>
          <description>Patients received in a sequential order the following interventional treatments : C, A and B.</description>
        </group>
        <group group_id="P5">
          <title>Sequence 5</title>
          <description>Patients received in a sequential order the following interventional treatments: A, C and B.</description>
        </group>
        <group group_id="P6">
          <title>Sequence 6</title>
          <description>Patients received in a sequential order the following interventional treatments: B, C and A.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject/Guardian Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All participants randomized to one of six treatment sequences</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.5" spread="14.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>FEV1 Standardized Area Under the Curve (AUC 0-24h) After Last Evening Dose of 14-day Treatment Period</title>
        <description>Weighted mean forced expiratory volume in 1 second (FEV1) over 24 h (AUC0-24h) following 14 days of treatment with QVM149 dosed in the morning, QVM149 dosed in the evening and placebo.</description>
        <time_frame>At the end of each treatment period day 14 pre-dose to 24 hours post-dose.</time_frame>
        <population>The pharmacodynamic (PD) analysis set included all patients with any available PD data, who received any dose of study drug and experienced no protocol deviations with relevant impact on PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 am</title>
            <description>QVM149 150/50/80 μg o.d. (indacaterol acetate 150 μg/ glycopyrronium bromide 50 μg/ MF 80 μg once daily) administered in the morning (plus matching placebo in the evening)</description>
          </group>
          <group group_id="O2">
            <title>QVM149 pm</title>
            <description>QVM149 150/50/80 μg o.d. (indacaterol acetate150 μg/ glycopyrronium bromide 50 μg/ MF 80 μg once daily) administered in the evening (plus matching placebo in the morning)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered in the morning and in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 Standardized Area Under the Curve (AUC 0-24h) After Last Evening Dose of 14-day Treatment Period</title>
          <description>Weighted mean forced expiratory volume in 1 second (FEV1) over 24 h (AUC0-24h) following 14 days of treatment with QVM149 dosed in the morning, QVM149 dosed in the evening and placebo.</description>
          <population>The pharmacodynamic (PD) analysis set included all patients with any available PD data, who received any dose of study drug and experienced no protocol deviations with relevant impact on PD data.</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4305" spread="0.15242"/>
                    <measurement group_id="O2" value="3.4361" spread="0.15213"/>
                    <measurement group_id="O3" value="2.8209" spread="0.15259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.’</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.6096</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5380</ci_lower_limit>
            <ci_upper_limit>0.6811</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.’</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.6152</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5437</ci_lower_limit>
            <ci_upper_limit>0.6868</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.’</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.0057</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0760</ci_lower_limit>
            <ci_upper_limit>0.0647</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough FEV1 After 24h</title>
        <description>FEV1 at approximately 24 h after the last p.m. or penultimate a.m. dose. Morning and evening trough FEV1 (L) were analyzed by time of day. For morning trough FEV1 (L) assessments this meant that the spirometric assessment was done approximately 24 h after last morning dose and approximately 12 h after last evening dose.</description>
        <time_frame>At the end of each treatment period day 14 pre-dose to 24 hours post-dose.</time_frame>
        <population>The pharmacodynamic (PD) analysis set included all patients with any available PD data, who received any dose of study drug and experienced no protocol deviations with relevant impact on PD data</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 am</title>
            <description>QVM149 150/50/80 μg o.d. (indacaterol acetate 150 μg/ glycopyrronium bromide 50 μg/ MF 80 μg once daily) administered in the morning (plus matching placebo in the evening)</description>
          </group>
          <group group_id="O2">
            <title>QVM149 pm</title>
            <description>QVM149 150/50/80 μg o.d. (indacaterol acetate150 μg/ glycopyrronium bromide 50 μg/ MF 80 μg once daily) administered in the evening (plus matching placebo in the morning)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered in the morning and in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough FEV1 After 24h</title>
          <description>FEV1 at approximately 24 h after the last p.m. or penultimate a.m. dose. Morning and evening trough FEV1 (L) were analyzed by time of day. For morning trough FEV1 (L) assessments this meant that the spirometric assessment was done approximately 24 h after last morning dose and approximately 12 h after last evening dose.</description>
          <population>The pharmacodynamic (PD) analysis set included all patients with any available PD data, who received any dose of study drug and experienced no protocol deviations with relevant impact on PD data</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3731" spread="0.15037"/>
                    <measurement group_id="O2" value="3.4871" spread="0.15041"/>
                    <measurement group_id="O3" value="2.7524" spread="0.15120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.’</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.6206</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5335</ci_lower_limit>
            <ci_upper_limit>0.7077</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.’</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.7347</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6469</ci_lower_limit>
            <ci_upper_limit>0.8225</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.’</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1141</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1970</ci_lower_limit>
            <ci_upper_limit>-0.0311</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Expiratory Flow (PEF)</title>
        <description>Peak expiratory flow (PEF) is the maximum flow generated during a forceful exhalation, starting from full lung inflationDaily morning and evening peak expiratory flow rate from Day 2 to Day14 during the three treatment periods.</description>
        <time_frame>From treatment period start through study completion (up to 19 weeks).</time_frame>
        <population>The pharmacodynamic (PD) analysis set included all patients with any available PD data, who received any dose of study drug and experienced no protocol deviations with relevant impact on PD data</population>
        <group_list>
          <group group_id="O1">
            <title>QVM149 am</title>
            <description>QVM149 150/50/80 μg o.d. (indacaterol acetate 150 μg/ glycopyrronium bromide 50 μg/ MF 80 μg once daily) administered in the morning (plus matching placebo in the evening)</description>
          </group>
          <group group_id="O2">
            <title>QVM149 pm</title>
            <description>QVM149 150/50/80 μg o.d. (indacaterol acetate150 μg/ glycopyrronium bromide 50 μg/ MF 80 μg once daily) administered in the evening (plus matching placebo in the morning)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo administered in the morning and in the evening.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Expiratory Flow (PEF)</title>
          <description>Peak expiratory flow (PEF) is the maximum flow generated during a forceful exhalation, starting from full lung inflationDaily morning and evening peak expiratory flow rate from Day 2 to Day14 during the three treatment periods.</description>
          <population>The pharmacodynamic (PD) analysis set included all patients with any available PD data, who received any dose of study drug and experienced no protocol deviations with relevant impact on PD data</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Morning average PEF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="489.6" spread="19.77"/>
                    <measurement group_id="O2" value="504.4" spread="19.78"/>
                    <measurement group_id="O3" value="417.5" spread="19.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evening average PEF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="522.0" spread="19.71"/>
                    <measurement group_id="O2" value="507.7" spread="19.71"/>
                    <measurement group_id="O3" value="449.0" spread="19.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Morning average PEF</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.’</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>72.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>61.3</ci_lower_limit>
            <ci_upper_limit>82.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Morning average PEF</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.’</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>86.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>76.1</ci_lower_limit>
            <ci_upper_limit>97.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Morning average PEF</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.’</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-14.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.6</ci_lower_limit>
            <ci_upper_limit>-4.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Evening average PEF</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.’</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>73.1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>61.9</ci_lower_limit>
            <ci_upper_limit>84.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Evening average PEF</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.’</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>58.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>47.5</ci_lower_limit>
            <ci_upper_limit>69.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Evening average PEF</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>A hypothesis test is not planned for this study, inferences are to be performed by interpreting confidence interval of treatment difference.’</non_inferiority_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>14.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.3</ci_lower_limit>
            <ci_upper_limit>25.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 19 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>QVM149 a.m.</title>
          <description>QVM149 150/50/80 μg o.d. (indacaterol acetate 150 μg/ glycopyrronium bromide 50 μg/ MF 80 μg once daily) administered in the morning (plus matching placebo in the evening)</description>
        </group>
        <group group_id="E2">
          <title>QVM149 p.m.</title>
          <description>QVM149 150/50/80 μg o.d. (indacaterol acetate150 μg/ glycopyrronium bromide 50 μg/ MF 80 μg once daily) administered in the evening (plus matching placebo in the morning)</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo administered in the morning and in the evening</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceutical</organization>
      <phone>862-778-8300</phone>
      <email>novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

